On June 10, 2022 The SHINE Technologies reported that gearing up for this year’s SNMMI Annual Meeting, June 11-14 in Vancouver, British Columbia (Press release, Shine Medical Technologies, JUN 10, 2022, View Source [SID1234615878]). Leading molecular-imaging and nuclear-medicine professionals from every corner of the industry will come together to share in-depth views of the latest research and development, as well as share insights into practical clinical applications.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
After two years of holding virtual events, we’re excited to attend SNMMI’s first in-person conference since 2019. This year’s theme is "Advancing Precision Imaging and Therapy."
We’ll be sharing progress on our diagnostics and therapeutics divisions during exhibit hours. Our proprietary isotope production processes create molybdenum-99 and non-carrier-added lutetium-177 used in tens of thousands of daily procedures to diagnose and treat heart disease and late-stage cancer. Our contribution to these markets will increase access to life-saving capabilities, including improving industrial equipment safety and diagnosing and treating cancer, heart disease, and other illnesses.
We are already producing lutetium-177 on a small scale for preclinical and clinical trials, and our process was validated for Good Manufacturing Practice earlier this year. We plan to continue to scale production of Lu-177 on the way to our large-scale production facility going online in 2024.
Our large-scale molybdenum-99 production facility is expected to be the largest facility in the world dedicated solely to producing medical isotopes. It is slated to go online late next year.
Chris Vessell, SHINE’s new General Manager of the Therapeutics Division, will be in attendance.
"I am excited to bring my experience to such a talented, visionary team at SHINE," said Vessell. "Their technology and vision for the future will be a game-changer as the company continues to pioneer new methods of nuclear medicine and delivers cancer therapies that make immeasurable differences for patients and their families."
If you want to say "hi" to Chris, or learn how SHINE Technologies is working to help improve medical outcomes through fusion technology, stop by and see us at Booth No. 36 at the show. If you have any questions in advance, send us a note at [email protected] or visit our virtual booth.